Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The incidence and prevalence of chronic kidney disease (CKD) are increasing worldwide and are associated with poor outcomes. According to the 1999–2004 National Health and Nutrition Examination Survey (NHANES), the prevalence of CKD among the USA population is 15.3% [1]. Although there is still some controversy whether CKD represents an independent causal risk factor for incident cardiovascular disease (CVD), accumulating evidence over the last decade marks out CVD as the major cause of mortality in patients with mild to moderate CKD and end-stage renal disease (ESRD) [2, 3]. It becomes apparent that the severity of CKD along with CVD severity in any population makes a ‘devastated’ combination for both patients and healthcare systems. Approximately 50% of patients with ESRD die from a cardiovascular event [4], which indicates a cardiovascular mortality that is 30 times higher in dialysis patients and 500 times higher in 25- to 34-year-old ESRD patients than in individuals from the general population of the same age and race [2, 4]. Premature CVD extends from mild to moderate stages of CKD. A pooled analysis of four community-based studies showed that moderate renal insufficiency carries a 19% excess risk of cardiovascular complications [5]. In a retrospective cohort study only a tiny minority of patients (0.5–1%) with mild to moderate CKD developed ESRD over a 5-year follow-up, while as many as 19 and 24% of these patients with mild and moderate renal insufficiency, respectively, died mostly of cardiovascular complications in the same period [6].In the general population as much as 75% of the excess risk of coronary heart disease could be explained by traditional Framingham risk factors [7]. However, use of traditional risk factors underestimates the CVD risk in patients with CKD [8], while the Framingham predictive instrument demonstrates poor overall accuracy in predicting cardiac events in patients with mild to moderate CKD [9]. Moreover, traditional CVD risk factors were found often to relate to outcome in ESRD dialysis patients in an opposite direction, a phenomenon termed ‘reverse epidemiology’ [10]. The introduction of uremia-related, non-traditional CVD risk factors and evaluation of their corresponding biomarkers were thought to enhance the clinical ability to predict cardiovascular events in patients with all stages of CKD. However, studies investigating the usefulness of current CVD biomarkers have concluded that they only add moderately to traditional risk factors for risk assessment of individuals both with almost normal renal function [11] as well as with mild to moderate CKD [12, 13].Dyslipidemia has been established as a well-known traditional risk factor for CVD in the general population and large-scale observational studies have shown that total and low-density lipoprotein (LDL)-cholesterol values are two of the most important independent predictors of cardiovascular morbidity and mortality [14]. Also, it is well known that patients with impaired renal function exhibit significant alterations in lipoprotein metabolism, which in their most advanced form may result in the development of severe dyslipidemia. In this review studies on the pathogenesis of renal dyslipidemia and the results of drug therapy are discussed.The process of exogenous and endogenous pathways of lipid metabolism is a complicated phenomenon in both normal and abnormal conditions. A schematic presentation of both pathways is shown in figure 1.Although lipid abnormalities were originally considered as complications of ESRD, these changes can be present in early stages of CKD and may actively participate in the pathogenesis of serious complications such as atherosclerotic vascular disease. Although the nature of dyslipidemia can be significantly influenced by several intrinsic (nephrotic range proteinuria, concomitant diseases such as diabetes mellitus, hereditary disorders of lipid metabolism) or exogenous (epoietin administration, drugs such as steroids, calcineurin inhibitors, etc.) factors, the most common quantitative lipid abnormalities in predialysis CKD patients are hypertriglyceridemia, increased concentrations of triglyceride-rich lipoprotein remnants, reduced high-density lipoprotein (HDL)-cholesterol levels as well as increased concentrations of lipoprotein(a) (Lp(a)) [15]. Notably, total and LDL-cholesterol levels are usually within normal limits or slightly reduced in these individuals (table 1) [16].Hypertriglyceridemia represents an early feature of renal failure. Indeed, previous studies have shown that patients with impaired renal function exhibit increased concentrations of triglycerides even though serum creatinine levels are within normal limits [17, 18]. In addition, individuals with renal insufficiency usually display abnormal increases in serum triglyceride levels after a fat meal (postprandial lipemia) [19]. Experimental studies revealed that the accumulation of triglyceride-rich lipoproteins (very-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919 · cited 1×
“studies that utilized simvastatin and atorvastatin, respectively. In addition, the recently published ALERT study revealed that although the administration of fluvastatin in renal transplant recipients did not significantly reduce the risk of the composite primary end point (cardiac death, nonfatal myocardial infarcti…”
ResultSt-Pierre, A. C., Cantin, B., Dagenais, G. R., Mauriège, P., Bernard, P.-M., Després, J.-P., & Lamarche, B. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000154144.73236.f4 · Cited by 422 · cited 1×
“These particles are more atherogenic than the large, buoyant ones and can substantially contribute to the pathogenesis of atherosclerotic vascular disease [”
BackgroundSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · cited 1×
“The administration of ω–3 polyunsaturated fatty acids may also play a role in the management of this extremely rare condition [”
BackgroundLipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Cheng, H.-T., Huang, J.-W., Chiang, C.-K., Yen, C.-J., Hung, K.-Y., & Wu, K.-D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2658 · Cited by 140
Tsimihodimos, V., & Elisaf, M. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328345ebb0 · Cited by 33
Self-citationChen, Y.-R., Lin, S.-B., Lv, J.-Y., Wu, Y., & Feng, W.-R. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124865 · Cited by 25
Metadata
- Authors
- Tsimihodimos, V., Dounousi, E., & Siamopoulos, K. C.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 28
- Issue
- 6
- Pages
- 958-973
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2078397566
- Cited by
- 146
- References
- 12
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment. https://app.cochat.ai/papers/10.1159/000144024
- The paper
- Tsimihodimos, V., Dounousi, E., & Siamopoulos, K. C. (2008). Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment. American Journal of Nephrology. https://doi.org/10.1159/000144024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.